ERC Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
ERC Pharma
Largest movements
- Receivables within one year -€125,898
down €125,898 (-27.4%), from €458,970 to €333,072
- Debts after one year -€332,685
down €332,685 (-16.5%), from €2.0m to €1.7m
- Profit (loss) carried forward -€179,975
down €179,975 (-118.4%), from -€151,962 to -€331,937
- Current portion of long-term debt +€165,909
up €165,909 (+83.7%), from €198,111 to €364,020
- Other debts +€99,253
up €99,253 (+6.4%), from €1.5m to €1.6m
- Trade debts +€97,617
up €97,617 (+8944.4%), from €1,091 to €98,708
- Financial charges +€23,081
up €23,081 (+27.8%), from €83,131 to €106,212
- Gross operating margin -€11,429
down €11,429 (-23.2%), from -€49,253 to -€60,682
- Depreciation -€6,743
down €6,743 (-30.9%), from €21,812 to €15,069
- Other operating charges +€3,262
up €3,262 (+3262.2%), from €100 to €3,362
- Financial income +€3,016
up €3,016 (+129.2%), from €2,334 to €5,350
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €3,699,179 | €3,558,176 | -€141,002 | -3.8% |
| Formation expenses | 20 | €1,570 | €1,177 | -€392 | -25.0% |
| Fixed assets | 21/28 | €3,238,604 | €3,223,927 | -€14,677 | -0.5% |
| Tangible fixed assets | 22/27 | €590,104 | €575,427 | -€14,677 | -2.5% |
| Land and buildings | 22 | €590,104 | €575,427 | -€14,677 | -2.5% |
| Financial fixed assets | 28 | €2,648,500 | €2,648,500 | = | 0.0% |
| Current assets | 29/58 | €459,005 | €333,072 | -€125,933 | -27.4% |
| Amounts receivable within one year | 40/41 | €458,970 | €333,072 | -€125,898 | -27.4% |
| Other amounts receivable | 41 | €458,970 | €333,072 | -€125,898 | -27.4% |
| Cash at bank and in hand | 54/58 | €36 | - | -€36 | |
| Total equity and liabilities | 10/49 | €3,699,179 | €3,558,176 | -€141,002 | -3.8% |
| Equity | 10/15 | -€51,962 | -€231,937 | -€179,975 | -346.4% |
| Contributions | 10/11 | €100,000 | €100,000 | = | 0.0% |
| Capital | 10 | - | €100,000 | +€100,000 | |
| Issued capital | 100 | - | €100,000 | +€100,000 | |
| Outside capital | 11 | €100,000 | - | -€100,000 | |
| Other | 1109/19 | €100,000 | - | -€100,000 | |
| Profit (loss) carried forward | 14 | -€151,962 | -€331,937 | -€179,975 | -118.4% |
| Amounts payable | 17/49 | €3,751,141 | €3,790,114 | +€38,973 | +1.0% |
| Amounts payable after more than one year | 17 | €2,012,678 | €1,679,994 | -€332,685 | -16.5% |
| Financial debts | 170/4 | €2,012,678 | €1,679,994 | -€332,685 | -16.5% |
| Amounts payable within one year | 42/48 | €1,738,462 | €2,110,120 | +€371,658 | +21.4% |
| Current portion of amounts payable after more than one year | 42 | €198,111 | €364,020 | +€165,909 | +83.7% |
| Financial debts | 43 | - | €5,531 | +€5,531 | |
| Credit institutions | 430/8 | - | €5,531 | +€5,531 | |
| Trade debts | 44 | €1,091 | €98,708 | +€97,617 | +8944.4% |
| Suppliers | 440/4 | €1,091 | €98,708 | +€97,617 | +8944.4% |
| Taxes, remuneration and social security | 45 | - | €3,348 | +€3,348 | |
| Taxes | 450/3 | - | €3,348 | +€3,348 | |
| Other amounts payable | 47/48 | €1,539,260 | €1,638,512 | +€99,253 | +6.4% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €21,812 | €15,069 | -€6,743 | -30.9% |
| Other operating charges | 640/8 | €100 | €3,362 | +€3,262 | +3262.2% |
| Gross operating margin | 9900 | -€49,253 | -€60,682 | -€11,429 | -23.2% |
| Operating profit (loss) | 9901 | -€71,165 | -€79,113 | -€7,948 | -11.2% |
| Financial income | 75/76B | €2,334 | €5,350 | +€3,016 | +129.2% |
| Recurring financial income | 75 | €2,334 | €5,350 | +€3,016 | +129.2% |
| Financial charges | 65/66B | €83,131 | €106,212 | +€23,081 | +27.8% |
| Recurring financial charges | 65 | €83,131 | €106,212 | +€23,081 | +27.8% |
| Profit (loss) for the period before taxes | 9903 | -€151,962 | -€179,975 | -€28,013 | -18.4% |
| Profit (loss) for the period | 9904 | -€151,962 | -€179,975 | -€28,013 | -18.4% |
| Profit (loss) for the period to be appropriated | 9905 | -€151,962 | -€179,975 | -€28,013 | -18.4% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 7 October 2026 via checked.be.